Barclays’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Barclays’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-31,037	Closed	-$66.7K	–	5455
2023 Q3	$66.7K	Sell	31,037 -374,782	-92%	-$774K	﹤0.01%	3743
2023 Q2	$735K	Buy	405,819 +388,241	+2,209%	+$710K	﹤0.01%	2515
2023 Q1	$23.2K	Buy	17,578 +8,359	+91%	+$13.7K	﹤0.01%	4628
2022 Q4	$15.6K	Buy	9,219 +7,204	+358%	+$9.13K	﹤0.01%	4857
2022 Q3	$4K	Sell	2,015 -39,538	-95%	-$118K	﹤0.01%	4557
2022 Q2	$127K	Sell	41,553 -1,247	-3%	-$7.61K	﹤0.01%	3671
2022 Q1	$309K	Buy	+42,800	New	+$421K	﹤0.01%	3191

Barclays's PRDS Position: Q4 2023 in Review

Barclays sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q4 2023, closing a stake of 31,037 shares — an estimated $66.7K sold.

Barclays first reported a position in PRDS in Q1 2022 and held it in 7 quarters. The position peaked at $735K in Q2 2023. 0 funds tracked by Wall St. Rank hold PRDS as of Q4 2023.

Barclays reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Barclays sold 31,037 Pardes Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $66.7K.
Barclays first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
Barclays's Pardes Biosciences, Inc. Common Stock position peaked at $735K in Q2 2023.
0 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q4 2023.

Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.